Curated news and analysis on clinical trials, drug approvals, and medical research.
Compass Pathways announced successful Phase 3 trial results for COMP360, a synthetic psilocybin treatment for treatment-resistant depression, showing rapid onset and durable effects with a 40% response rate after two doses.
Zydus Lifesciences launched ANYRA, India's first indigenous Aflibercept biosimilar for retinal conditions, and secured approval for a March 2026 day-one launch of generic semaglutide for diabetes and obesity treatment.
Research identifies orphan nuclear receptor SHP (NR0B2) as a novel regulator of osteoarthritis progression, demonstrating that it protects cartilage by inhibiting IKKβ/NF-κB signaling and reducing matrix-degrading enzyme expression in chondrocytes.
The FDA announced plans to restrict GLP-1 active pharmaceutical ingredients for compounded drugs and combat misleading advertising, following the Trump administration's launch of TrumpRx and ongoing enforcement actions against compounding pharmacies.
The U.S. share of global innovative drug trials has declined from the mid-40% range a decade ago to the low-30% range, while China's share has climbed steadily toward 30%, narrowing the gap between the two countries in pharmaceutical R&D competition.
Novel CELMoD agents are being evaluated to address T-cell exhaustion in multiple myeloma patients, while CAR T-cell therapy CARVYKTI shows longer-term survival benefits. Nearly 200,000 people in the U.S. live with this blood cancer.
Novartis announced plans to establish a 46,000-square-foot radioligand therapy manufacturing site in Denton, Texas, as part of its $23 billion US expansion. The facility is expected to be operational in 2028.
Eli Lilly's oral GLP-1 drug orforglipron showed superior blood sugar control and weight loss compared to oral semaglutide in a year-long trial of over 1,500 patients with type 2 diabetes.
Merck announced Phase 3 trial results for its investigational once-daily, two-drug HIV regimen doravirine/islatravir at CROI 2026, demonstrating non-inferiority to standard treatment in treatment-naïve adults with viral suppression rates of 91.8% at Week 48.
Researchers develop ultra-sensitive CAR-T cells targeting CD70 for solid tumors and KRASG12V/HLA-A*02:01-specific CAR-T cells for cancers with KRAS mutations, demonstrating efficacy in preclinical models.
A clinical trial combining laser interstitial thermal therapy with pembrolizumab shows nearly half of patients with recurrent high-grade astrocytoma alive at 18 months, compared to zero in the control group.
ImmunityBio completed enrollment of 366 patients in its Phase 2 trial of ANKTIVA plus BCG versus BCG alone for BCG-naïve bladder cancer. Interim analysis showed statistically significant improvement in duration of complete response, with the company anticipating a BLA submission by Q4 2026.
New research shows cancer survivors who exercise reduce their risk of cancer-related death, while expert panel recommends exercise as essential for older cancer patients during and after treatment.
Izalontamab brengitecan demonstrated statistically significant improvements in progression-free survival and overall survival compared to chemotherapy in patients with previously treated metastatic triple-negative breast cancer, marking the third Phase III success for the bispecific ADC.
A multi-institutional study found that pairing an investigational immunotherapy with hormone therapy before surgery reduced regulatory T cells in prostate tumors and improved cancer-free outcomes in high-risk patients.
New research reveals red blood cells absorb large amounts of glucose in low-oxygen conditions, explaining why high-altitude populations have lower diabetes rates. A drug mimicking this effect completely reversed high blood sugar in diabetic mice.
Phase 2 trial of amivantamab in recurrent/metastatic adenoid cystic carcinoma achieved 72.2% clinical benefit rate with good tolerability. Combination therapy with pembrolizumab is being evaluated in head and neck squamous cell cancer.
NeuraLight will present a neuroprogression biomarker that outperforms the current gold standard for tracking Parkinson's disease progression at the AD/PD 2026 conference in Copenhagen beginning March 17.
Crinetics Pharmaceuticals reported over $5 million in preliminary net product revenue for PALSONIFY in Q4 2025, while Phase 2 data for its congenital adrenal hyperplasia treatment showed promising results that analysts say have derisked the Phase 3 study design.
The CAR T-Cell Therapy Market is estimated to reach USD 13.78 billion by 2031 from USD 7.24 billion in 2026, at a CAGR of 13.7%. The Cell & Gene Therapy Drug Delivery Devices Market is forecast to climb to USD 26.79 billion by 2032 from USD 3.39 billion in 2025.
